First patient enrolled in Inari DEFIANCE trial for deep vein thrombosis

Inari Medical has announced that the first patient has been enrolled in the DEFIANCE trial. This trial will evaluate the clinical results of Inari’s ClotTriever System for the treatment of deep vein thrombosis (DVT).

DEFIANCE is a prospective randomised clinical trial (RCT) which will feature 300 DVT patients at up to 60 centres globally. The idea is to compare the results of patients treated with ClotTriever compared to those on anticoagulant treatment only.

ClotTriever is an over-the-wire system. It works by mechanically coring clot from the vein wall by capturing and removing large clot burden from big vessels.

Inari Medical chief medical officer Thomas Tu said: “With six major clinical studies, including two ongoing RCTs, Inari is wholly committed to VTE patients and producing definitive evidence to support our technologies. None of this is possible without the collaboration and dedication of our clinical trial investigators who continually push the field forward in the name of better patient outcomes.”

Dr. Abdullah Shaikh, an interventional radiologist at Allegheny Health Network in Pittsburgh, Pennsylvania, US, enrolled the first patient in the DEFIANCE trial, commented: “We’re thrilled to enrol the first patient and officially kick off this important clinical trial. ClotTriever is fundamentally different than other DVT treatments. This trial is designed to produce definitive evidence to change standard of care.”

James Spargo